LYMPHOMA (including CLL)  

H 8701; CD34-selection for ex vivo T-cell depletion of mobilized peripheral blood stem cells for recipients of HLA haploidentical related donor stem cell grafts receiving intensive conditioning: This study uses a monoclonal antibody and high dose chemotherapy and radiotherapy combined with haploidentical allogeneic stem cell transplantation to treat pediatric patients with hematologic malignancies.

H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H: This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.

H9936; Administration Of LMP Specific Cytotoxic T-Lymphocytes To Patients With Relapsed EBV-Positive Hodgkin Disease: This study uses autologous EBV specific T-Lymphocytes targeting the EBV proteins LMP1 and LMP2 to treat lymphoma.

H11967: Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) with Human IL-2 and CD40 Ligand Plasmid Gene Modified Autologous Tumor Cells: This study uses autologous gene modified tumor cells (also referred to as a vaccine) which release  IL-2 and CD40L to treat patients with CLL. 

H12472; Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients with Hematological Diseases: This study uses monoclonal antibodies and low dose chemotherapy and radiotherapy combined with allogeneic stem cell transplantation.

H11892; A Current Practice Study Of Rituxan In Patients Receiving BEAM Chemotherapy And Autologous Blood Stem Cell Transplantation For High Risk Lymphoma And Hodgkin's Disease: This study uses a monoclonal antibody and high dose chemotherapy combined with autologous stem cell transplantation.

H17656: Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) with Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells after Depletion of Regulatory T Cells: This study uses a combination of monoclonal antibodies and autologous gene modified tumor cells (also referred to as a vaccine) which release  IL-2 and CD40L to treat patients with CLL. 

H17946: Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma: This study uses EBV specific T-Lymphocytes with a gene inserted to render them resistant to TGF-b to treat lymphoma.

H19275: Administration of LMP1- AND LMP2-specific Cytotoxic T-Lymphocytes following CD45 Antibody to Patients with Relapsed EBV-Positive Hodgkin’s or non-Hodgkin’s Lymphoma: This study uses a combination of monoclonal antibodies and  autologous EBV specific T-Lymphocytes to treat lymphoma.

H19747: Prolonged Immunisation with Autologous CD40 Ligand and IL-2-expressing Tumor Cells for Treatment of B-Chronic Lymphocytic Leukemia (B-CLL): This study uses autologous gene modified tumor cells (also referred to as a vaccine) which release  IL-2 and CD40L to treat patients with CLL given over a longer period of time than other studies listed above. 

H19164: T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation: This study  looks at T reg cells in patients receiving a haploidentical stem cell transplant following high dose chemotherapy and radiation therapy

H19384: Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia: This study uses a chimeric receptor made from T cells that kill tumor cells and an antibody called anti-CD19 that sticks to lymphoma cells to try to treat non-Hodgkin’s lymphoma and CLL.

H19386: Reduced -Intensity Preparative Regimen With Fludarabine, Busulfan, And Alemtuzumab Followed By Allogeneic Hematopoeitic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases: This study uses a monoclonal antibody and low dose chemotherapy combined with allogeneic stem cell transplantation to treat patients with hematologic disorders (both malignant and non-malignant) who also have other complications such as kidney, liver, or heart disease

H20971: Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis: The purpose of this study is to assess the safety and toxicity of low-dose IL-2 given to patients after receiving a Stem Cell Transplant and to determine whether this drug is helpful in preventing GVHD.

H22899: Phase I Study of the Administration of Peripheral Activated T-Cells or EBV specific CTLs Expressing CD19 Chimeric Receptors for Advanced B-Cell non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: This study uses a chimeric receptor made from T cells that kill tumor cells and an antibody called anti-CD19 that sticks to lymphoma cells to try to treat non-Hodgkin’s lymphoma and CLL.

©2002, Cell And Gene Therapy, Baylor College of Medicine
One Baylor Plaza, N1002, Houston, TX 77030, (713)798-1246
URL: http://www.bcm.edu/genetherapy Email:cagt@bcm.edu
(Modified: September 21st, 2007 - jb)